期刊文献+

124例Ⅱ期非精原细胞瘤治疗分析 被引量:1

A review of 124 cases of atage Ⅱ non-spermatocytoma
原文传递
导出
摘要 目的 比较Ⅱ期非精原细胞瘤不同治疗方法的疗效。 方法 将 12 4例Ⅱ期非精原细胞瘤患者按治疗方法不同分三组 ,其中单纯手术组 (A组 ) 4 5例 ,手术 +术后放疗组 (B组 ) 4 0例 ,手术 +术后化疗组 (C组 ) 39例。比较三组局部复发率 ,远处转移率 ,3、5年生存率。 结果 A组局部复发率为 37.8% ,远处转移率为 42 .2 % ,3、5年生存率分别为 5 7.8%、40 .0 % ;B组局部复发率、远处转移率 ,3、5年生存率分别与A组相近 ,P均 >0 .0 5 ;C组局部复发率与A、B组相近 (P >0 .0 5 ) ,但远处转移率低于A、B组 ,且 3、5年生存率分别高于A、B组 ,P均 <0 .0 5。 结论 本组Ⅱ期非精原细胞瘤 (畸胎瘤、胚胎癌 )经放疗不能改变预后 ,且该类肿瘤易出现血行播散 ,术后放疗往往会延误化疗的最佳时机。该类肿瘤对化疗敏感 ,不仅可以杀灭手术时业己形成的亚临床灶 ,而且可杀灭因手术造成的医源性播散 ,可望降低局部复发应率、远处转移率、延长生存期。 Objective To evaluate the treatment of stage II non-spermatocytoma. Methods 45 cases were treated by open operation alone,40 cases by operation and postoperativeradiotherapy and 39 ca- ses by chemotherapy and operation.The therapeutic results of these 3 groups were compared. Results In patients with open operation alone ,the recurrence rate was 37.8%,the distance metastasis rate 42.2%,the 3 year survival rate 57.8% and the 5 year survival rate 40.0%.These were similar in patients with operation and radiotherapy( P >0.05).In patients with operation and chemotherapy,the distand metastasis rate has been lower and the 3、5 year survival rates higher( P <0.05). Conclusions Radiotherapy is non-effective for stage Ⅱ or higher stage non-spermatocytoma whereas chemotherapy would reduce the metastasis rate and prolong the survival time.
出处 《中华泌尿外科杂志》 CAS CSCD 北大核心 2000年第11期681-682,共2页 Chinese Journal of Urology
关键词 睾丸肿瘤 Ⅱ期非精原细胞瘤 治疗 病例分析 Testicular neoplasms Therapeutics
  • 相关文献

参考文献2

  • 1张天泽,肿瘤学,1996年,1838页
  • 2汤钊猷,现代肿瘤学,1993年,417页

同被引文献10

  • 1梅骅 见:梅骅 主编.腹膜后淋巴结清除术[A].见:梅骅,主编.泌尿外科手术学[C].,..
  • 2.[M].北京:人民卫生出版社,1996.764-771.
  • 3Sheinfeld J, Mckiernan J, Bosl GJ. Retroperitoneal lymph node dissection. In Walsh PC, Retik AB,Vaughan ED,et al. Eds. Campell's Urology. 8th ed. Philadelphia: Saunders ,2002. 2925-2930.
  • 4Chang SS, Roth B. Treatment of clinical stage Ⅰ germ cell tumors.Urology, 2002,59:173 -179.
  • 5Jacobsen KD, Ous S, Waehre H, et al. Ejaculation in testicular cancer patients after post-chemotherapy retroperitoneal lymph node dissection. Br J Cancer, 1999,80:249-255.
  • 6Spermon JR, De Wilde PC, Hanselaar AG, et al. Alpha-catenin expression pattern and DNA image-analysis cytometry have no additional value over primary histology in clinical stage Ⅰ nonseminomatous testicular cancer. BJU Int,2002,89:278-284.
  • 7Weissbach L, Bussar-Maatz R, Flechtner H,et al. RPLND or primary chemotherapy in clinical stage ⅡA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. Eur Urol, 2000,37: 5 82 -594.
  • 8Rabbani F,Farivar-Mohseni H,Leon A,et al. Clinical outcome after retroperitoneal lymphadenectomy of patients with pure testicular teratoma. Urology,2003,62:1092-1096.
  • 9Nonomura N,Nishimura K,Takaha N,et al. Nerve-sparing retroperitoneal lymph node dissection for advanced testicular cancer after chemotherapy. Int J Urol,2002 ,9 :539-544.
  • 10Spermon JR, Roeleveld TA, van der Poel HG, et al. Comparison of surveillance and retroperitoneal lymph node dissection in Stage Ⅰ nonseminomatous germ cell tumors. Urology ,2002,59:923-929.

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部